Immunotherapy biomarkers for advanced lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study looks at blood and tissue biomarkers to predict how well immunotherapy (with or without chemotherapy) works for advanced non-small cell lung cancer. It also helps decide the best second treatment if the first one stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage 3B or 4 non-small cell lung cancer.
- You must not have certain gene changes (EGFR, ALK, ROS1) that are usually treated with other drugs.
- You must be starting or have recently started a standard immunotherapy drug (PD-1 or PD-L1 blocker), with or without chemotherapy, and had no more than 4 cycles so far.
- You must have tumor tissue available for testing from a recent biopsy or from a previous sample.
- You must agree to have extra blood drawn for research on circulating tumor DNA.
- You must have adequate kidney, liver, and blood cell counts, and be at least 18 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment for advanced non-small cell lung cancer that has stopped responding to targeted therapy and chemotherapy. The goal is to find a treatment that works better for people whose cancer has certain genetic changes.
This study is looking at biomarkers (clues in your blood and tumor) to better understand how advanced lung cancer responds to immunotherapy. It aims to help doctors predict which treatments might work best for you in the future.
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
This trial is comparing a new combination of two immunotherapy drugs (nivolumab and relatlimab) plus chemotherapy against the standard immunotherapy (pembrolizumab) plus chemotherapy for people with advanced non-squamous non-small cell lung cancer that has a certain protein (PD-L1) on at least 1% of its cells. The goal is to see if the new combination works better.
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Hear when a new Stage IIIB Lung Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.